Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut

Collegium Pharmaceutical is rated a high-risk Buy despite a sharp guidance cut and stock drop, which the article says may reflect an overly pessimistic market scenario. ADHD drugs Jornay PM and AZSTARYS now contribute over 30% of 2026 sales, are growing robustly and have patent protection into the 2030s. The pain franchise faces uneven risks: Nucynta has immediate generic pressure, Belbuca’s patent risk centers on an April 2027 trial, and Xtampza is protected until 2033.

Analysis

The key issue is not patent duration by itself but whether newer ADHD products can replace the earnings power lost from the pain franchise. A longer exclusivity runway limits one form of downside; it does not protect against weaker market-share gains, payer pressure, or pricing competition. Rising revenue concentration in two products also makes quarterly execution more consequential than the headline growth rate suggests.

Near term, the guidance reset can keep estimates and risk limits moving lower even if the selloff has over-discounted the eventual pain-drug decline. Over the next 1–3 months, look for stabilization in forward estimates and evidence that ADHD growth converts into durable net sales—not just prescription growth. Over 6–18 months, the staggered patent calendar gives management time to shift the portfolio, but litigation outcomes and the pace of generic erosion can pull risk forward. The April 2027 Belbuca trial is a medium-term volatility catalyst, not a present certainty of loss.

The contrarian case is that investors may be treating legacy-franchise erosion as simultaneous while underweighting the time available for portfolio transition. The counterpoint is that patent protection is not a substitute for demonstrated commercial economics. Falsify the recovery thesis if ADHD net sales or guidance decelerate, pain erosion accelerates beyond management’s assumptions, or litigation materially weakens expected exclusivity. Verify product-level net pricing, contribution economics, and the company’s updated erosion assumptions before sizing beyond a starter position.

Key Decisions for Investors

• Consider a small, staged long in COLL only after the next report confirms ADHD net-sales growth and management holds or improves product-level expectations; add only as estimate revisions stabilize. No price target is supportable from the supplied information.
• Keep downside defined: use a modest share position or a limited-risk call spread rather than an unhedged options position. Avoid adding ahead of the next earnings update if estimates are still being cut.
• Track three thesis breakers: ADHD net sales and prescription-to-revenue conversion, actual Nucynta/Belbuca/Xtampza erosion versus guidance, and material developments in the Belbuca patent case. Reassess promptly if any deteriorate.
• Do not treat patent dates as guaranteed commercial value. Before increasing exposure, verify litigation status, payer/net-price trends, and whether the growing ADHD portfolio contributes enough economically to offset pain-franchise decline.